Network Version
(-)-Epigallocatechin Gallate Data Sheet
| Product Name: | (-)-Epigallocatechin Gallate |
 |
|---|---|---|
| CAS No.: | 989-51-5 | |
| Cat. No.: | HY-13653 | |
| MWt: | 458.37 | |
| Formula: | C22H18O11 | |
| Purity : | >98% | |
| Solubility: | DMSO : ≥ 30 mg/mL | |
| Mechanisms: | Target: Cancer Inflammation/Immunology | |
| Biological Activity: | ||
| (-)-Epigallocatechin Gallate (EGCG) is a major polyphenol in green tea, which can inhibit cell proliferation and induce cell apoptosis. (-)-Epigallocatechin Gallate inhibits glutamate dehydrogenase 1/2 (GDH1/2, GLUD1/2) activity. (-)-Epigallocatechin Gallate has a potent anticancer, antioxidant and anti-inflammatory properties against various types of cancers such as colorectal cancer, myeloid leukemia, thyroid carcinoma[1][2][3][4]. IC50 & Target:EGFR, HER2 and HER3[1] GDH1/2, GLUD1/2[2] In Vitro:(-)-Epigallocatechin Gallate (EGCG, 10-60 μM) inhibits the growth of FB-2 and WRO cells in a dose-dependent manner[1]. (-)-Epigallocatechin Gallate (10-60 μM, 0-24 h) reduces cyclin D1 and phosphorylation of AKT and ERK1/2, and increases p21 and p53 expression[1]. (-)-Epigallocatechin Gallate (10-60 μM, 12 h) reduces cell motility and migration[1]. (-)-Epigallocatechin Gallate (0-20 μM, 0-20 min approximately) inhibits GLUD1/2 and IDH1 activity in a concentration and time-dependent way (biochemical assays)[2]. (-)-Epigallocatechin Gallate (0-35 μg/mL, 24-72 h) inhibits the proliferation of colorectal cancer cells (LoVo, SW480, HT-29, HCT-8 cells), increases cell apoptosis and blocks cells at the G0/G1 phase[3]. (-)-Epigallocatechin Gallate (30 μM, 3-24 h) suppresses the expression of COX-2 and mPGES-1 mRNAs, prostaglandin E2 production in LPS-induced osteoblasts[4]. In Vivo:(-)-Epigallocatechin Gallate (Intragastrical administration, 5-20 mg/kg, once daily for 14 days, orthotopic transplant model) decreases tumors growth[3]. (-)-Epigallocatechin Gallate (Injected into the mouse lower gingiva, a single dose of 0.5 mg/mouse, experimental periodontitis model) decreases inhibits the LPS-induced loss of bone mineral density (BMD)[3]. | ||
1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA
Tel: 609-228-6898 Fax: 609-228-5909 Email: [email protected] Web:www.medchemexpress.com